entity dossier
Blueprint
Blueprint is bryan johnson's longevity protocol, product company, and public measurement system. It began as Project Blueprint, an N=1 effort to measure Johnson's organs and biological aging, and later became a consumer brand selling products and protocols intended to make parts of Johnson's health system easier to follow.
// Habits · Longterm · Don’ts
Blueprint: habits, longterm, and don’ts
Three buckets keep practical routines, long-range interpretation, and source-aware caution visible on every protocol surface.
Habits
- Emphasize food quality and repeatability: plant-led meals, legumes/vegetables/healthy fats, earlier eating, and consistent prep.
concepts/blueprint-protocol.md - Pair product or testing claims with source paths so readers can distinguish Blueprint marketing from independent evidence.
concepts/blueprint-protocol.md - Treat the Akkermansia + butyrate product as supplement/product positioning until product-specific outcome evidence is available.
raw/articles/bryan-johnson/x-twitter-daily-2026-06-19.md
Longterm
- Keep nutrition as one input in the measurement loop rather than a standalone promise of rejuvenation.
concepts/blueprint-protocol.md - Update exact calories, macros, and meal windows only when a current source supports the number.
raw/articles/bryan-johnson/bryan-johnson-protocol-2026-05-22.md - Treat Johnson’s November 2026 chef-RHR post as an attributed N=1 measurement-loop disclosure, not evidence quantifying food→RHR effects. “My chef get’s my sleep resting heart rate every am. / My AI auto sends. / After 1,800+ days of experimentation, I know the exact impact of meal timing, food composition, and calories on my resting heart rate. / 42 bpm and below: 😃 / 43-45 bpm: 😐 / 45 bpm+: 🙁” operationalizes the tracked RHR storyline — the October 16 “Resting heart is the new thirst trap” status-engineering disclosure and the RHR-as-outcome-predictor context (CMAJ 2016 meta-analysis of 46 cohorts, 1,246,203 adults, 10.1503/cmaj.150535: each 10 bpm higher RHR associated with all-cause mortality RR 1.09; RHR >80 bpm at RR 1.45) — by routing the morning number to his chef via AI auto-send. Boundaries: “exact impact” is a self-report — no dataset, effect sizes, or confounder control is published for the claimed 1,800+ days, during which meals varied alongside sleep, training, travel, and illness; the 42 / 43–45 / 45+ emoji bands are personal traffic-light thresholds, not clinical bands; RHR moves for many reasons unrelated to food; and a predictor of mortality is not proof that meal-timing-driven RHR changes extend life. Not a reader meal-timing protocol, a validated food→RHR quantification, or medical advice.
https://x.com/bryan_johnson/status/2116979494699647184 - Treat Johnson’s October 2026 diet-timing immune directive as an attributed relay of a one-day-old Nature mouse study, not reader eating guidance. “Avoid eating dirty during an acute immune reaction bc it can permanently lock in how immune cells react in the future. *viral infection, autoimmune flare, tissue injury…” traces to Jiang, Tayeri, … Bapat, “Diet at disease onset determines tissue inflammatory memory,” Nature, published October 28, 2026 (10.1038/s41586-026-11181-4) — one day before the post: a 4-day high-fat window at imiquimod-inflammation onset amplified type-17 skin inflammation in lean mice to obesity-comparable severity (~2.1-fold ear thickening), and after recovery on low-fat food a chromatin-poised tissue-resident memory CD4+ T-cell population persisted, keeping rechallenges exaggerated out to 6.5 months — transplantable with the skin patch, abolished by NLRP3 inhibition at the initial flare or CD4 depletion, and mirrored acutely in lung. Boundaries: mice and a psoriasis-like cream model; tissue-local memory (only previously inflamed ears overreacted); 6.5 months is not “permanent”; “how immune cells react” at large overstates a skin CD4+ T_RM population; the viral/autoimmune/tissue-injury list extends to triggers the paper did not test; the corresponding author’s own caution is that a lab mouse diet “doesn’t map neatly onto what we eat.” Not a reader eating-during-illness protocol, evidence about human disease course, or medical advice.
https://x.com/bryan_johnson/status/2115894638561415459 - Treat the October 2026 five-item microplastics-reduction checklist as attributed exposure-reduction guidance with real measurement literature behind each item — microwaving plastic releases up to 4.22M microplastics and 2.11B nanoplastics per cm² in 3 minutes (ES&T 2023), plastic cutting boards shed an estimated 7.4–50.7 g/person-year (10.1021/acs.est.3c00924), plastic teabags release ~11.6 billion microplastics per cup vs 0.3–2.4 particles/cup for loose leaf (10.1021/acs.est.9b02540; npj Science of Food October 2026 head-to-head) — but no study yet demonstrates that reducing these exposures improves human health outcomes, and the post names no study. Not a reader purchasing list, proven health-benefit evidence, or medical advice.
https://x.com/bryan_johnson/status/2114496819615187026 - Treat Johnson’s October 2026 semen-microplastics relay as two real studies carried accurately around an unreplicable N=1 centerpiece. The studies verify: Hu/Garcia/Campen et al., Toxicological Sciences, August 2024 (10.1093/toxsci/kfae060) found microplastics in all 47 canine and all 23 human testes (human mean 328.44 µg/g, PE dominant) with the authors’ own limits — postmortem samples, method still being refined, “do not imply causality” — and the eBioMedicine multi-site China study (10.1016/j.ebiom.2024.105369) found microplastics in all semen and urine samples of 113 fertility-clinic men with PTFE exposure associated with lower sperm concentration (52.13 vs 58.32 million/mL — the post’s “11%” is 10.6% rounded) and total sperm count (188.90 vs 207.67 million — the “9%”), a cross-sectional association the authors explicitly separate from causation. But “I got mine to zero. The first documented case” is a self-reported specialty-lab test with no published method or replication — Johnson’s own reply concedes the test “is not widely available” and was created for him — and field-wide methodology reviews (Arch Toxicol 2026, 10.1007/s00204-026-04392-1) flag unstandardized detection and contamination risk that cut at “zero” and “100%” claims alike. Not evidence that non-stick pans harm readers’ fertility, a validated zero-microplastics protocol, or medical advice.
https://x.com/bryan_johnson/status/2115135756490747981
Don’ts
- Do not publish prototype calorie, macro, supplement-dose, or eating-window numbers as universal targets.
concepts/biomarker-driven-longevity-protocols.md - Do not treat Retatrutide commentary as medication guidance.
raw/articles/bryan-johnson/x-twitter-bryan-johnson-2026-05-22.md - Do not treat microplastics testing or product claims as proven intervention efficacy.
raw/articles/bryan-johnson/blueprint-microplastics-test-2026-05-23.md
Blueprint
Blueprint is bryan johnson’s longevity protocol, product company, and public measurement system. It began as Project Blueprint, an N=1 effort to measure Johnson’s organs and biological aging, and later became a consumer brand selling products and protocols intended to make parts of Johnson’s health system easier to follow.
What it is
Blueprint has three overlapping meanings:
- Project Blueprint — the original self-experiment announced in 2021 to measure 70+ organs and reverse quantified biological age markers.
- Blueprint Protocol — the evolving set of routines/interventions covering sleep, exercise, nutrition, oral care, skin/hair, clean water, biomarkers, and advanced therapies.
- Blueprint company/product layer — a commercial system of food, supplements, tests, and health guidance. TIME reports Blueprint sells supplements, skincare, haircare, olive oil, and aging tests, and that it raised $60M from investors.
Product thesis
The homepage describes Blueprint as “The most nutritious food program in history” and “67 health interventions based upon 1,000+ clinical trials.” The Protocol page is more expansive: it attempts to turn health into a game where people learn to “flex” biomarkers and adopt fewer, higher-leverage behaviors.
Johnson’s X/Twitter positioning compresses the thesis: “Blueprint is automation that first achieves peak health and then self-drives to age escape velocity.”
Recent commercial expansion (June 2026)
Blueprint’s public product layer now includes more than food, supplements, tests, and skincare. In June 2026 Johnson highlighted two newer commercial directions:
- Prescription therapeutics: a Longevity Rx / Immortals medical layer offering clinician-mediated access to drugs Johnson says he personally uses, including Tadalafil, Metformin, Oral Minoxidil, Tretinoin, Estradiol, and Acarbose.
- Microbiome supplement: a Blueprint product built around Akkermansia muciniphila plus butyrate triglycerides, described as a “capsule within a liquid capsule.” Johnson frames it around gut-barrier, glucose-regulation, and metabolic-health mechanisms.
Both are product-positioning signals. They belong on the dashboard because they show where Blueprint is moving commercially, but the health claims should be read as Johnson/Blueprint claims unless independently validated.
Evidence posture
Blueprint is unusual because Johnson publishes more personal measurements and routines than most wellness founders. Its strongest components are boring health fundamentals: sleep, exercise, nutrient-dense diet, oral care, social/behavioral discipline, reduced alcohol/sugar/junk food, and measurement.
Its weaker or more contested components are the extreme stack: many supplements, intensive diagnostics, peptide/gene/stem-cell/plasma experiments, and claims around organ ages or biological age reversal. Critics argue that one person changing many interventions simultaneously cannot isolate cause, and that biomarkers are surrogate endpoints rather than proven lifespan extension.
Relationship to Don’t Die
Blueprint is the practical body-level implementation of dont die. Don’t Die supplies the ideology: survival, anti-entropy, AI-era civilization alignment. Blueprint supplies the consumer-facing habits, products, protocols, and biomarkers.
Open questions
- Which Blueprint interventions have independently reproducible effect sizes beyond Johnson’s N=1 data?
- Can Blueprint separate product marketing from scientific claims tightly enough to earn mainstream clinical trust?
- Will its best contribution be specific products/protocols, or the broader cultural reframing of health as measurable infrastructure?